IOVANCE BIOTHERAPEUTICS INC
NASDAQ: IOVA (Iovance Biotherapeutics, Inc.)
Kemas kini terakhir: 2 jam lalu3.79
-0.04 (-1.04%)
| Penutupan Terdahulu | 3.83 |
| Buka | 3.80 |
| Jumlah Dagangan | 22,359,680 |
| Purata Dagangan (3B) | 12,735,118 |
| Modal Pasaran | 1,504,508,544 |
| Harga / Jualan (P/S) | 2.95 |
| Harga / Buku (P/B) | 1.17 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| Margin Keuntungan | -176.49% |
| Margin Operasi (TTM) | -245.76% |
| EPS Cair (TTM) | -1.22 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 6,798.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 7.00% |
| Nisbah Semasa (MRQ) | 4.18 |
| Aliran Tunai Operasi (OCF TTM) | -334.39 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -184.76 M |
| Pulangan Atas Aset (ROA TTM) | -27.14% |
| Pulangan Atas Ekuiti (ROE TTM) | -51.85% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Iovance Biotherapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | -0.50 |
|
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.37% |
| % Dimiliki oleh Institusi | 81.26% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Mhr Fund Management Llc | 31 Dec 2025 | 28,967,103 |
| Invenomic Capital Management Lp | 31 Dec 2025 | 11,959,505 |
| Long Focus Capital Management, Llc | 31 Dec 2025 | 8,600,000 |
| Palo Alto Investors Lp | 31 Dec 2025 | 7,116,676 |
| Hrt Financial Lp | 31 Dec 2025 | 4,356,010 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 11.00 (Barclays, 190.24%) | Beli |
| Median | 8.00 (111.08%) | |
| Rendah | 5.00 (Citizens, 31.93%) | Beli |
| Purata | 8.00 (111.08%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 3.83 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Barclays | 25 Feb 2026 | 11.00 (190.24%) | Beli | 3.83 |
| 17 Dec 2025 | 10.00 (163.85%) | Beli | 2.52 | |
| Citizens | 25 Feb 2026 | 5.00 (31.93%) | Beli | 3.83 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |